Assyro AI

Purple Book product · Reference 351(a)

Humate-P

Antihemophilic Factor/von Willebrand Factor Complex (Human)

351(a)BLA 103960RxLicensed CSL Behring GmbH

Apr 11, 2000

Approved

Reference 351(a)

License type

Rx

Marketing

None

Listed patents

Humate-P (Antihemophilic Factor/von Willebrand Factor Complex (Human)) is CSL Behring GmbH's FDA-licensed reference biologic, approved under a 351(a) BLA in 2000. No biosimilars referencing Humate-P are listed in the Purple Book yet.

Sourced from the FDA Purple Book · verified Jul 02, 2026

Key dates

  1. Approval

    Approval date of this BLA submission.

    Apr 11, 2000

    26 yr 8 mo ago

  2. Orphan exclusivity ends

    7-year orphan-drug exclusivity window.

    Apr 01, 2006

    20 yr 7 mo ago

  3. Today

Pharmaceutical detail

Strength

250IU

Dosage form

For Injection

Route

Intravenous

Presentation

Single-Dose Vial

Center

CBER

License number

1765

Product number

002

Submission type

Original

Supplement number

0

Change type

Not listed

Reference product family

View full family

This is the reference (originator) product. No biosimilars or interchangeables reference it in the Purple Book yet.

2 additional BLA records for this product (other strengths or presentations) are in the same reference family.

Patent list

No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.

Source provenance

Source kind · Advanced Search
Checked Jul 02, 2026
  • advanced-searchAdvanced Search · Jul 02, 2026
  • monthly-downloadMonthly download · Jul 02, 2026

Change history

  • v6Jul 02, 2026
  • v5Jul 02, 2026
  • v4Jul 02, 2026
  • v3Jul 02, 2026
  • v2Jul 02, 2026

Frequently asked questions

Does Humate-P have approved biosimilars?

No 351(k) biosimilars or interchangeable biosimilars referencing Humate-P are listed in the FDA Purple Book yet.

What is Humate-P's BLA number?

Humate-P is licensed under BLA 103960, held by CSL Behring GmbH.

When was Humate-P approved by the FDA?

Humate-P was approved by the FDA on Apr 11, 2000.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.